Last week a Tekmira executive told me they would be entitled to a milestone payment in the event of FDA approval, but he did not specify the amount. He also pointed out that Talon has two other drugs in early stage development that have licensed delivery technology from Tekmira. He said it would be a lucrative franchise for Tekmira should all Talon's drugs with licensed delivery technology be approved, but explained Tekmira was focused on sRNAi, and was not actively pursuing the re-packaging of other existing drugs. The disappointing drop in the price of Talon's shares after the positive ODAC vote may be more about the certain near-term dilution of the stock than about the prospects of FDA approval. In early April shareholders vote on a proposed increase in authorized shares to 600 million. I'm guessing there'll be a secondary offering immediately after the vote; management won't have the guts to wait for the FDA decision on May 13, even though approval would save existing shareholders a big stake in the company.